The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.
 
Michael J Ciesielski
Employment - MimiVax
Leadership - MimiVax
Stock and Other Ownership Interests - MimiVax
Research Funding - MimiVax
Patents, Royalties, Other Intellectual Property - SurVaxM Patents
 
Manmeet Singh Ahluwalia
Stock and Other Ownership Interests - CytoDyn; doctible; MedInnovate Advisors LLC; MimiVax
Honoraria - Elsevier; Peerview; Prime Education; Prime Oncology
Consulting or Advisory Role - Apollomics; Bayer; Celularity; GlaxoSmithKline; InSightec; Janssen; KIYATEC; Novocure; Nuvation Bio; Prelude Therapeutics; SDP Oncology; ViewRay; Voyager Therapeutics; Xoft
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); MimiVax (Inst); Novartis (Inst); Novocure (Inst); Pharmacyclics (Inst)
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Ajay P. Abad
No Relationships to Disclose
 
William T. Curry
(OPTIONAL) Uncompensated Relationships - IMRIS
 
Eric T. Wong
Honoraria - Advanced Medical; Novocure; UpToDate; Zai Lab
Research Funding - Five Prime Therapeutics; Novocure; Orbus Therapeutics; Plexxikon; Vascular Biogenics
 
David M. Peereboom
Honoraria - Elsevier
Consulting or Advisory Role - Orbus Therapeutics; Sumitomo Dainippon Pharma Oncology, Inc.
Research Funding - Apollomics; Bayer; Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Karyopharm Therapeutics; Karyopharm Therapeutics; Mylan (Inst); Neonc Technologies (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics; Stemline Therapeutics (Inst)
 
Sheila A. Figel
Research Funding - MimiVax
 
Alan Hutson
No Relationships to Disclose
 
Adrienne Groman
No Relationships to Disclose
 
Henry G. Withers
No Relationships to Disclose
 
Song Liu
No Relationships to Disclose
 
Ahmed Belal
No Relationships to Disclose
 
Jing-Xin Qiu
Honoraria - Merck
Consulting or Advisory Role - Merck
Speakers' Bureau - Merck
 
Kathleen Mogensen
No Relationships to Disclose
 
Cathy Schilero
No Relationships to Disclose
 
Danielle M. Casucci
Employment - MimiVax
 
Laszlo Mechtler
No Relationships to Disclose
 
Robert Alan Fenstermaker
Stock and Other Ownership Interests - MimiVax
Patents, Royalties, Other Intellectual Property - I hold several patents for technology related to cancer vaccines, antibodies and related cellular therapies